Citations

Clear

1792 citation(s) found for "Stephanie".

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health
Larkin, Lisa , Stuenkel, Cynthia A. , Bachmann, Gloria , Chism, Lisa Astalos, Kagan, Risa , Kaunitz, Andrew M., Krychman, Michael , Parish, Sharon J. , Pinkerton, JoAnn V. , Rowen, Tami S., Shapiro, Marla , Simon, James A. , Goldfarb, Shari, Kingsberg, Sheryl A. , Faubion, Stephanie S. , Partridge, Ann H.

Mayo Clinic

Menopause | May 15, 2018 | Volume: 25 | Issue: 6 | Pages: 596-608

10.1097/gme.0000000000001121 | PMID 29762200 Get It

Abstract The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. The Expert Consensus Panel is comprised of a diverse group of 16 multidisciplinary experts well respected in their fields. The panelists individually conducted an evidence-based review of the literature in their respective areas of expertise. They then met to discuss the latest treatment options for genitourinary syndrome of menopause (GSM) in survivors of breast cancer and review management strategies for GSM in women with or at high risk for breast cancer, using a modified Delphi method. This iterative process involved presentations summarizing the current literature, debate, and discussion of divergent opinions concerning GSM assessment and management, leading to the development of consensus recommendations for the clinician. Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies. The paucity of evidence regarding the safety of vaginal hormone therapies in women with or at high risk for breast cancer has resulted in avoidance of treatment, potentially adversely affecting quality of life and intimate relationships. Factors influencing decision-making regarding treatment for GSM include breast cancer recurrence risk, severity of symptoms, response to prior therapies, and personal preference. We review current evidence for various pharmacologic and nonpharmacologic therapeutic modalities in women with a history of or at high risk for breast cancer and highlight the substantial gaps in the evidence for safe and effective therapies and the need for future research. Treatment of GSM is individualized, with nonhormone treatments generally being first line in this population. The use of local hormone therapies may be an option for some women who fail nonpharmacologic and nonhormone treatments after a discussion of risks and benefits and review with a woman's oncologist. We provide consensus recommendations for an approach to the management of GSM in specific patient populations, including women at high risk for breast cancer, women with estrogen-receptor positive breast cancers, women with triple-negative breast cancers, and women with metastatic disease.
Vasomotor symptoms in women over 60: results from the Data Registry on Experiences of Aging, Menopause, and Sexuality (DREAMS)
David, Paru S., Kling, Juliana M. , Vegunta, Suneela , Kapoor, Ekta , Mara, Kristin C. , Schroeder, Darrell R. , Hilsaca, Karla Frohmader, Kuhle, Carol L. , Mara, Kristin C , Kling, Juliana M , Schroeder, Darrell , Faubion, Stephanie S. , Hilsaca, Karla S. Frohmader

Mayo Clinic

Menopause | May 9, 2018 | Volume: 25 | Issue: 10 | Pages: 1105-1109

10.1097/gme.0000000000001126 | PMID 29738420 Get It

Abstract Objective: Frequency of vasomotor symptoms (VMS) in older women and the contributing factors are largely undefined. We measured the frequency of moderate-to-severe vasomotor symptoms (msVMS) in women ≥60 years of age and examined their characteristics to determine factors that may associate with VMS in older women. Methods: A cross-sectional survey was completed using the Menopause Health Questionnaire from the Data Registry on Experiences of Aging, Menopause, and Sexuality. Data were collected from women presenting for menopause consultation to Mayo Clinic, Rochester, MN, from January 1, 2006 to October 7, 2014. We created a binary variable where women were classified as having msVMS bother if they reported “quite a bit” or “extremely” compared with women reporting “not at all” or “a little bit.” Women with and without msVMS were evaluated by menopause type, self-rated heath, current tobacco, caffeine, and alcohol use, as well as pertinent medication use. Associations between participant characteristics and msVMS were evaluated using logistic regression and a multivariable model with age as a covariate. Interactions between participant characteristics and age were also assessed. Results: Of the 4,956 women presenting for menopause consultation, 921 (18%) were ≥60 years old. Of these, 379 (41.2%) reported msVMS bother. Women with msVMS were more likely to have a history of nonspontaneous menopause and report their health as fair, versus good or excellent. Women reporting current use of hormone therapy (HT) (21%) were less likely to report msVMS compared with those not taking HT (P < 0.001). Conclusions: A substantial number of women seen in a specialty menopause clinic were over age 60 years and reported msVMS, highlighting that VMS may be disruptive in women over a decade past the natural age of menopause.
SLCO1B1 genetic variation and hormone therapy in menopausal women
Moyer, Ann M. , Kapoor, Ekta , Dudenkov, Tanda M., Weinshilboum, Richard M. , Miller, Virginia M. , de Andrade, Mariza, Dudenkov, Tanda, Andrade, Mariza de , Faubion, Stephanie S. , Weinshilboum, Richard M.

Mayo Clinic

Menopause | May 9, 2018 | Volume: 25 | Issue: 8 | Pages: 877-882

10.1097/gme.0000000000001109 | PMID 29738412 Get It

Abstract Objective: Response to menopausal hormone therapy (MHT) shows individual variation. SLCO1B1 encodes the OATP1B1 transporter expressed in the liver that transports many endogenous substances, including estrone sulfate, from the blood into hepatocytes. This study evaluated the relationship between genetic variation in SLCO1B1 and response to MHT in women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS) at Mayo Clinic, Rochester, MN. Methods: KEEPS participants were randomized to oral conjugated equine estrogen (n = 33, oCEE), transdermal 17β-estradiol (n = 33, tE2), or placebo (n = 34) for 48 months. Menopausal symptoms (hot flashes, night sweats, insomnia, palpitations) were self-reported before treatment and at 48 months. Estrone (E1), E2, and sulfated conjugates (E1S, E2S) were measured using high-performance liquid chromatography-tandem mass spectrometry. SLCO1B1 rs4149056 (c.521T>C, p.Val174Ala) was genotyped using a TaqMan assay. Results: After adjusting for treatment, there was a significant association between the SLCO1B1 rs4149056 TT genotype (encoding normal function transporter) and lower E1S, E1S/E1, and E2S (P = 0.032, 0.010, and 0.008, respectively) compared with women who were heterozygous (TC) or homozygous (CC) for the reduced function allele. The interactions between genotype, treatment, and E2S concentration were stronger in women assigned to tE2 (P = 0.013) than the women taking oCEE (P = 0.056). Among women assigned to active treatment, women with the CT genotype showed a significantly greater decrease in night sweats (P = 0.041) than those with the TT genotype. Conclusions: Individual variation in sulfated estrogens is explained, in part, by genetic variation in SLCO1B1. Bioavailability of sulfated estrogens may contribute to relief of night sweats.
HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes
Wang, Sophia , Carrington, Mary , Berndt, Sonja I. , Bracci, Paige M. , Smedby, Karin E. , Hjalgrim, Henrik , Vijai, Joseph , Morton, Lindsay M. , Vermeulen, Roel , Paltiel, Ora , Vajdic, Claire M. , Linet, Martha S. , Nieters, Alexandra , Sanjosé, Sílvia de, Brown, Elizabeth E. , Turner, Jennifer , Spinelli, John J., Zheng, Tongzhang, Birmann, Brenda M. , Flowers, Christopher R. , Becker, Nikolaus, Holly, Elizabeth A., Kane, Eleanor , Weisenburger, Dennis D. , Cocco, Pierluigi, Weinstein, Stephanie J. , Diver, W. Ryan , Lax, S. , Travis, Ruth C., Kaaks, Rudolph, Ríboli, Elio , Benavente, Yolanda , Brennan, Paul, McKay, James , Delfau‐Larue, Marie‐Hélène , Link, Brian K. , Magnani, Corrado , Latte, Giancarlo, Doo, Nicole Wong , Offit, Kenneth , Musinsky, Jacob, Arslan, Alan A. , Purdue, Mark P. , Adami, Hans‐Olov , Melbye, Mads , Glimelius, Bengt , Conde, Lucía , Camp, Nicola J. , Glenn, Martha, Curtin, Karen , Clavel, Jacqueline , Monnereau, Alain, Cox, David G. , Ghesquières, Hervé , Salles, Gilles , Bofetta, Paulo, Foretová, Lenka , Staines, Anthony , Davis, S. Scott , Severson, Richard K., Lan, Qing , Brooks‐Wilson, Angela , Smith, Martyn T. , Roman, Eve , Kricker, Anne , Zhang, Yawei , Kraft, Peter , Rothman, Nathaniel , Hartge, Patricia, Skibola, Christine F., Cocco, Pierluigi , Travis, Ruth C. , Monnereau, Alain , Turner, Jennifer , Weinstein, Stephanie J , Link, Brian K , Joseph, Vijai , Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Arslan, Alan A , Travis, Ruth C , Kraft, Peter , Morton, Lindsay M , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Riboli, Elio , Slager, Susan L. , Voutsinas, Jenna M. , Cerhan, James R. , Cozen, Wendy , Maynadié, Marc , Albanes, Demetrius , Teras, Lauren R. , Ennas, Maria Grazia , Feldman, Andrew L. , Giles, Graham G. , Southey, Melissa C. , Milne, Roger L. , Chanock, Stephen Jacob , Doo, Nicole Wong

Mayo Clinic

Cancer Research | May 7, 2018 | Volume: 78 | Issue: 14 | Pages: 4086-4096

10.1158/0008-5472.can-17-2900 | PMID 29735552 Get It

Abstract A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of “heterozygote advantage” regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06–1.60; OR MZL = 1.45, 95% CI = 1.12–1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24–3.55; OR MZL = 2.10, 95% CI = 0.99–4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend &lt; 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. Cancer Res; 78(14); 4086–96. ©2018 AACR.
Copy number variant analysis using genome‐wide mate‐pair sequencing
Smadbeck, James B. , Johnson, Sarah H. , Smoley, Stephanie A., Gaitatzes, Athanasios , Drucker, Travis, Zenka, Roman M. , Kosari, Farhad , Hoppman, Nicole L., Sukov, William R. , Jenkins, Robert B. , Kearney, Hutton M. , Vasmatzis, George , Drucker, Travis M, Hoppman, Nicole, Aypar, Umut , Murphy, Stephen J. , Feldman, Andrew L.

Mayo Clinic

Genes, Chromosomes and Cancer | May 4, 2018 | Volume: 57 | Issue: 9 | Pages: 459-470

10.1002/gcc.5 | PMID 29726617 Get It

AbstractCopy number variation (CNV) is a common form of structural variation detected in human genomes, occurring as both constitutional and somatic events. Cytogenetic techniques like chromosomal microarray (CMA) are widely used in analyzing CNVs. However, CMA techniques cannot resolve the full nature of these structural variations (i.e. the orientation and location of associated breakpoint junctions) and must be combined with other cytogenetic techniques, such as karyotyping or FISH, to do so. This makes the development of a next‐generation sequencing (NGS) approach capable of resolving both CNVs and breakpoint junctions desirable. Mate‐pair sequencing (MPseq) is a NGS technology designed to find large structural rearrangements across the entire genome. Here we present an algorithm capable of performing copy number analysis from mate‐pair sequencing data. The algorithm uses a step‐wise procedure involving normalization, segmentation, and classification of the sequencing data. The segmentation technique combines both read depth and discordant mate‐pair reads to increase the sensitivity and resolution of CNV calls. The method is particularly suited to MPseq, which is designed to detect breakpoint junctions at high resolution. This allows for the classification step to accurately calculate copy number levels at the relatively low read depth of MPseq. Here we compare results for a series of hematological cancer samples that were tested with CMA and MPseq. We demonstrate comparable sensitivity to the state‐of‐the‐art CMA technology, with the benefit of improved breakpoint resolution. The algorithm provides a powerful analytical tool for the analysis of MPseq results in cancer.
Novel Common Genetic Susceptibility Loci for Colorectal Cancer
Schmit, Stephanie L. , Edlund, Christopher K., Schumacher, Fredrick R. , Harrison, Tabitha A. , Huyghe, Jeroen R. , Qu, Chenxu, Melas, Marilena , Berg, David Van Den , Wang, Hansong, Tring, Stephanie, Plummer, Sarah J. , Alonso, M. Henar , Anton, Kristen , Aragaki, Aaron K. , Arndt, Volker , Barry, Elizabeth L. , Berndt, Sonja I. , Bloomer, Amanda M. , Boehm, Juergen , Brenner, Hermann , Brezina, Stefanie , Buchanan, Daniel D. , Butterbach, Katja, Caan, Bette J. , Carlson, Christopher S. , Castelao, Jose E. , Chang‐Claude, Jenny , Cheng, Ya‐Wen , Chin, Lee Soo, Church, Timothy R. , Correa, Marcia Cruz, Curtis, Keith R. , Duggan, David , Easton, Douglas F. , English, Dallas R. , Fischer, Rocky, Fritsche, Lars G. , Fuchs, Charles S. , Gago-Domínguez, Manuela , Gala, Manish , Gallinger, Steven , Gauderman, W. James, Giovannucci, Edward L. , Gogarten, Stephanie M. , González‐Villalpando, Clicerio, Gonzalez-Villalpando, Elena M., Greenson, Joel K. , Gsur, Andrea , Gunter, Marc J. , Haiman, Christopher A. , Hampe, Jochen , Harlid, Sophia , Harju, John F., Hayes, Richard B. , Hofer, Philipp , Hoffmeister, Michael , Huang, Shu-Chen, Huerta, José María , Hunter, David J., Idos, Gregory , Jackson, Rebecca D. , Jacobs, Eric J. , Jee, Sun Ha , Jenkins, Mark A. , Jia, Wei-Hua , Jiao, Shuo , Joshi, Amit D. , Kolonel, Laurence N. , Kono, Suminori , Krogh, Vittorio , Küehn, Tilman, Küry, Sébastien , LaCroix, Andrea Z. , Laurie, Cecelia , Lejbkowicz, Flavio, Lemire, Mathieu , Lenz, Heinz‐Josef , Levine, David , Li, Li , Lindor, Noralane M. , Liu, Yun-Ru, Lu, Yingchang , Luh, Frank , Ma, Jing , Mancao, Christoph , Manion, Frank J. , Markowitz, Sanford D. , Martín, Vicente , Matsuo, Keitaro , McDonnell, Kevin , McNeil, Caroline E, Murphy, Neil , Offit, Kenneth, Omichessan, Hanane , Cotoré, Jesús Paredes, Pérez‐Mayoral, Julyann, Rennert, Gad , Rennert, Hedy S., Riggs, Bridget M., Schafmayer, Clemens, Sellers, Thomas A. , Seminara, Daniela, Shibata, David , Siegel, Erin M. , Slattery, Martha L. , Stintzing, Sebastian , Taverna, Darin, Thibodeau, Stephen N. , Thomas, Duncan C. , Trichopoulou, Antonia , Duijnhoven, Fränzel J.B. van , Guelpan, Bethany van, Virtamo, Jarmo, Weinstein, Stephanie J. , Win, Aung Ko , Woods, Michael O. , Wu, Anna H. , Wu, Kana , Xiang, Yong-Bing , Zanke, Brent W., Zeng, Yi-Xin , Zhang, Ben , Zubair, Niha, Figueiredo, Jane C. , Lindblom, Annika , Moreno, Vı́ctor , Peters, Ulrike , Conti, David V. , Gruber, Stephen B. , Kühn, Tilman , Buchanan, Daniel D , Win, Aung K , Rennert, Gad , Hoffmeister, Michael , Arndt, Volker , English, Dallas R , Martín, Vicente , Moreno, Victor , Gunter, Marc J , Jenkins, Mark A , Van Den Berg, David J , Harrison, Tabitha A , Matsuo, Keitaro , Kury, Sebastien , Brenner, Hermann , Gago-Dominguez, Manuela , Hampe, Jochen , Murphy, Neil , Hayes, Richard B , Brezina, Stefanie , Conti, David V , Gong, Jian Feng , Albanes, Demetrius , Amos, Christopher I. , Bezieau, Stéphane , Bien, Stephanie A. , Boutron‐Ruault, Marie‐Christine , Campbell, Peter T. , Chan, Andrew T. , Chanock, Stephen Jacob , Cheng, Iona C. , Church, James M. , Coetzee, Gerhard A. , Cotterchio, Michelle , Feskens, Edith J. M. , FitzGerald, Liesel M. , Fortini, Barbara K. , Giles, Graham G. , Grady, William M. , Hopper, John L. , Hudson, Thomas J , Iwasaki, Motoki , Kooperberg, Charles , Li, Christopher I , Lieb, Wolfgang , Lin, Yi , Liu, Yun‐Ru , Loupakis, Fotios , Matsuda, Koichi , McNeil, Caroline E, Milne, Roger L. , Molina, Antonio José , Mukherjee, Bhramar , Newcomb, Polly A. , Palli, Domenico , Pharoah, Paul D.P. , Potter, John D. , Qu, Conghui , Raskin, Leon , Schoen, Robert E. , Severi, Gianluca , Shi, Wei , Shu, Xiao‐Ou , Southey, Melissa C. , Stadler, Zsofia , Stern, Mariana Carla , Tsugane, Shoichiro , Ulrich, Cornelia M. , Vijai, Joseph , White, Emily E. , Wolk, Alicja , Yen, Yun , Kweon, Sun-Seog , Zheng, Wei , Marchand, Loı̈c Le , Casey, Graham , Church, Timothy R , Caan, Bette J , Lindblom, Annika

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 30, 2018 | Volume: 111 | Issue: 2 | Pages: 146-157

10.1093/jnci/djy099 | PMID 29917119 Get It

Abstract Background Previous genome-wide association studies (GWAS) have identified 42 loci (P < 5 × 10−8) associated with risk of colorectal cancer (CRC). Expanded consortium efforts facilitating the discovery of additional susceptibility loci may capture unexplained familial risk. Methods We conducted a GWAS in European descent CRC cases and control subjects using a discovery–replication design, followed by examination of novel findings in a multiethnic sample (cumulative n = 163 315). In the discovery stage (36 948 case subjects/30 864 control subjects), we identified genetic variants with a minor allele frequency of 1% or greater associated with risk of CRC using logistic regression followed by a fixed-effects inverse variance weighted meta-analysis. All novel independent variants reaching genome-wide statistical significance (two-sided P < 5 × 10−8) were tested for replication in separate European ancestry samples (12 952 case subjects/48 383 control subjects). Next, we examined the generalizability of discovered variants in East Asians, African Americans, and Hispanics (12 085 case subjects/22 083 control subjects). Finally, we examined the contributions of novel risk variants to familial relative risk and examined the prediction capabilities of a polygenic risk score. All statistical tests were two-sided. Results The discovery GWAS identified 11 variants associated with CRC at P < 5 × 10−8, of which nine (at 4q22.2/5p15.33/5p13.1/6p21.31/6p12.1/10q11.23/12q24.21/16q24.1/20q13.13) independently replicated at a P value of less than .05. Multiethnic follow-up supported the generalizability of discovery findings. These results demonstrated a 14.7% increase in familial relative risk explained by common risk alleles from 10.3% (95% confidence interval [CI] = 7.9% to 13.7%; known variants) to 11.9% (95% CI = 9.2% to 15.5%; known and novel variants). A polygenic risk score identified 4.3% of the population at an odds ratio for developing CRC of at least 2.0. Conclusions This study provides insight into the architecture of common genetic variation contributing to CRC etiology and improves risk prediction for individualized screening.
Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn’s Disease: An International Multicenter Study
Calabrese, Emma , Kucharzik, Torsten , Maaser, Christian , Strobel, Deike , Zorzi, Francesca, Novak, Kerri L. , Bruining, David H. , Iacucci, Marietta , Watanabe, Mamoru , Lolli, Elisabetta , Chiaramonte, Carlo, Pallone, Francesco, Ghosh, Subrata , Monteleone, Giovanni , Wilson, Stephanie R, Maconi, Giovanni , Wilson, Stephanie R. , Hanauer, Stephen B. , Panaccione, Remo , Iacucci, Marietta

Mayo Clinic

Inflammatory Bowel Diseases | April 28, 2018 | Volume: 24 | Issue: 9 | Pages: 2001-2006

10.1093/ibd/izy091 | PMID 29718450 Get It

0504 Predictive Ability And Reliability Of The Stop-Bang Questionnaire In Screening For Obstructive Sleep Apnea In Midlife Women
Orbea, Cinthya Peña, Lloyd, Robin M. , Kapoor, Ekta , Miller, Virginia M. , Kapoor, Ekta , Mara, Kristin C. , Faubion, Stephanie S.

Mayo Clinic

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A189-A189

10.1093/sleep/zsy061.503 Get It

Early Hospital Discharge After Helicopter Transport of Pediatric Trauma Patients
Fahy, Aodhnait S. , Polites, Stephanie F. , Parker, Maile E., Ishitani, Michael B., Moir, Christopher R. , Berns, Kathleen S., Zietlow, Scott P., Jenkins, Donald H. , Zielinski, Martin D. , Berns, Kathleen, Thiels, Cornelius A.

Mayo Clinic

Pediatric Emergency Care | April 24, 2018 | Volume: 36 | Issue: 12 | Pages: e709-e714

10.1097/pec.0000000000001481 | PMID 29698341 Get It

Objectives Helicopter air ambulance (HAA) of pediatric trauma patients is a life-saving intervention. Triage remains a challenge for both scene transport and interhospital transfer of injured children. We aimed to understand whether overtriage or undertriage was a feature of scene or interhospital transfer and how in or out of state transfers affected these rates. Methods Children (<18 years) who underwent trauma activation at a level I trauma center between 2011 and 2013 were identified and reviewed. Patients transported by HAA were compared with those transported by ground ambulance (GA). Results Of 399 pediatric patients (median age, 10.4 years; range, 0.1–17 years; 264 male [66%]), 71 (18%) were transported by HAA. Seventy-two percent of HAA patients went to the intensive care unit or the operating room from the trauma bay or suffered in-hospital mortality (vs 42% GA, P < 0.001). More patients were overtriaged (HAA with injury severity score [ISS] of <15) from interhospital transfers than from the scene (25% vs 3%, P = 0.002). Undertriage (GA with ISS >15) was acceptable at 5% from the scene and 14% from interhospital transfers (P = 0.08). Overtriage of patients with ISS less than 15 to HAA was significantly lower from in-state hospitals (22%) than out-of-state hospitals (45%) (P = 0.02). Undertriage of patients with ISS greater than 15 to GA was also lower from in-state hospitals (20%) versus out-of-state hospitals (38%) (P = 0.03). Conclusions Triage of pediatric trauma patients to HAA remains difficult. There remains potential for improvement, particularly as regards interhospital HAA overtriage, but well developed transfer protocols (such in-state protocols) may help.
Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn’s Disease
Deepak, Parakkal , Fidler, Jeff L. , Barlow, John M. , Sheedy, Shannon P. , Kolbe, Amy B. , Harmsen, William S. , Therneau, Terry M. , Becker, Brenda D., Loftus, Edward V. , Bruining, David H. , Loftus, Edward V , Deepak, Parakkal , Fletcher, Joel G. , Fidler, Jeff L. , Hansel, Stephanie L.

Mayo Clinic

Inflammatory Bowel Diseases | April 13, 2018 | Volume: 24 | Issue: 8 | Pages: 1815-1825

10.1093/ibd/izy074 | PMID 29668921 Get It